Loading…
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-541M | $-513M | $-422M | -50.6% | - | - |
| 2024 | $0M | $-493M | $-423M | $-364M | -34.4% | -100.0% | - |
| 2023 | $331M | $-180M | $-145M | $-371M | -14.1% | 204.7% | - |
| 2022 | $108M | $-330M | $-326M | $-263M | -31.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 108.46 | 330.53 | 0 | 0 |
| Operating Expense | 449.21 | 527.23 | 501.88 | 555.34 |
| Operating Income | -340.74 | -196.70 | -501.88 | -555.34 |
| EBITDA | -330.36 | -179.97 | -492.89 | -540.53 |
| EBIT | -340.74 | -196.70 | -501.88 | -555.34 |
| Pretax Income | -325.97 | -145.19 | -422.70 | -512.44 |
| Tax Provision | 0.02 | 0.03 | 0.07 | 0.10 |
| Net Income | -325.99 | -145.22 | -422.77 | -512.54 |
| Net Income Common Stockholders | -325.99 | -145.22 | -422.77 | -512.54 |
| Total Expenses | 449.21 | 527.23 | 501.88 | 555.34 |
| Interest Income | 14.77 | 51.51 | 64.64 | 42.90 |
| Research And Development | 358.73 | 423.88 | 396.44 | 418.78 |
| Selling General And Administration | 90.47 | 103.35 | 105.44 | 136.56 |
| Normalized EBITDA | -330.36 | -179.97 | -507.42 | -540.53 |
| Normalized Income | -325.99 | -145.22 | -434.26 | -512.54 |
| Basic EPS | -2.60 | -1.06 | -2.57 | 0 |
| Diluted EPS | -2.60 | -1.06 | -2.57 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 3.05 | 0 |
| Tax Rate For Calcs | 0 | 0.21 | 0.21 | 0 |
| Total Unusual Items | 0 | 0 | 14.54 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | 14.54 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -325.99 | -145.22 | -422.77 | -512.54 |
| Reconciled Depreciation | 10.38 | 16.73 | 8.99 | 14.81 |
| Net Interest Income | 14.77 | 51.51 | 64.64 | 42.90 |
| Net Income From Continuing And Discontinued Operation | -325.99 | -145.22 | -422.77 | -512.54 |
| Total Operating Income As Reported | -340.74 | -196.70 | -487.34 | -555.34 |
| Diluted Average Shares | 125.53 | 137.37 | 164.47 | 0 |
| Basic Average Shares | 125.53 | 137.37 | 164.47 | 0 |
| Diluted NI Availto Com Stockholders | -325.99 | -145.22 | -422.77 | -512.54 |
| Net Income Including Noncontrolling Interests | -325.99 | -145.22 | -422.77 | -512.54 |
| Net Income Continuous Operations | -325.99 | -145.22 | -422.77 | -512.54 |
| Other Income Expense | 0 | 0 | 14.54 | 0 |
| Special Income Charges | 0 | 0 | 14.54 | 0 |
| Gain On Sale Of Business | 0 | 0 | 14.54 | 0 |
| Net Non Operating Interest Income Expense | 14.77 | 51.51 | 64.64 | 42.90 |
| Total Other Finance Cost | 0 | 0 | 0 | 0 |
| Interest Income Non Operating | 14.77 | 51.51 | 64.64 | 42.90 |
| General And Administrative Expense | 90.47 | 103.35 | 105.44 | 136.56 |
| Other Gand A | 90.47 | 103.35 | 105.44 | 136.56 |
| Operating Revenue | 105.06 | 330.53 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Denali Therapeutics Inc.this co. | DNLI | $3.0B | - | 2.87 | -50.6% | -3.93 |
| Beam Therapeutics Inc. | BEAM | $3.0B | - | 2.35 | -6.5% | -5.05 |
| Alumis Inc. | ALMS | $2.9B | - | 7.95 | -80.8% | -6.02 |
| LifeStance Health Group, Inc. | LFST | $2.9B | 371.50 | 1.90 | 0.6% | 39.06 |
| Dyne Therapeutics, Inc. | DYN | $2.9B |
| - |
| 2.95 |
| -45.9% |
| -4.14 |
| Erasca, Inc. | ERAS | $2.8B | - | 7.96 | -38.3% | -20.28 |
| Arcutis Biotherapeutics, Inc. | ARQT | $2.8B | - | 14.56 | -8.5% | -352.93 |
| Haemonetics Corporation | HAE | $2.7B | 16.26 | 3.03 | 20.4% | 9.88 |
| Soleno Therapeutics, Inc. | SLNO | $2.7B | 135.33 | 6.13 | 4.6% | 145.68 |
| Peer Median | - | 135.33 | 4.58 | -7.5% | -4.60 | |